Full metadata record
DC FieldValueLanguage
dc.contributor.authorZHU Charlesen_GB
dc.contributor.authorBANDEKAR Ameyen_GB
dc.contributor.authorBANERJEE Sangeeta Rayen_GB
dc.contributor.authorPOMPER Martinen_GB
dc.contributor.authorBRUCHERTSEIFER Franken_GB
dc.contributor.authorMORGENSTERN Alfreden_GB
dc.contributor.authorSOFOU Stavroulaen_GB
dc.date.accessioned2014-08-01T00:08:44Z-
dc.date.available2014-07-31en_GB
dc.date.available2014-08-01T00:08:44Z-
dc.date.created2014-06-26en_GB
dc.date.issued2014en_GB
dc.date.submitted2014-01-27en_GB
dc.identifier.citationJOURNAL OF NUCLEAR MEDICINE vol. 55 no. Supplement 1 p. 640en_GB
dc.identifier.issn0161-5505en_GB
dc.identifier.urihttp://publications.jrc.ec.europa.eu/repository/handle/JRC88668-
dc.description.abstractWe study targeted liposomes loaded with the alpha-particle generator Actinium-225 (225Ac) to selectively kill prostate-specific-membrane-antigen-(PSMA)-expressing cells with the aim to evaluate their potential for targeted antivascular alpha-radiotherapy. This bottom-up design contains the following: The targeted moiety is PSMA which is unique to human tumor vasculature for several different types of primary human cancers. The therapeutic radionuclide,225Ac, emits a total of four alpha-particles per decay providing highly lethal and localized irradiation of targeted cells with minimal exposure of surrounding healthy tissues. Finally, the delivery carrier is a lipid-based nanocarrier (a liposome). Liposomes can be loaded with high levels of radioactivity, and, in terms of toxicities, liposomes can be easily engineered to become rapidly cleared from circulation with the aim to shift the distribution of normal organ toxicities away from the kidneys (the dose limiting organ for 225Ac-labeled antibodies) and toward the spleen and/or liver.en_GB
dc.description.sponsorshipJRC.E.5-Nuclear chemistryen_GB
dc.format.mediumPrinteden_GB
dc.languageENGen_GB
dc.publisherSOC NUCLEAR MEDICINE INCen_GB
dc.relation.ispartofseriesJRC88668en_GB
dc.titleAnti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapyen_GB
dc.typeArticles in periodicals and booksen_GB
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.